Mylan said on Monday it expected to launch the generic product “in several weeks” at a list price of $300, an unusual move considering the branded bestseller is still patent protected and major rival treatments have failed to get regulatory clearances.
Advertisement
Mylan N.V. (MYL) announced Monday that its US subsidiary will launch the first generic to EpiPen Auto-Injector (epinephrine injection, USP) at a list price of $300 per generic EpiPen two-pack carton.
It will be available in both 0.15-milligram and 0.30-milligram strengths, like the current version on the market.
Netherlands-based Mylan said on Monday it also intends to continue to market and distribute branded EpiPen.
The company charges $608 for a two-pack of the branded EpiPen.
The company disclosed that its earlier announcement of augmented patient assistance program and $300 savings card would remain in place for the brand product.
A 19-year-old man was found shot multiple times laying in a Union County road, Sunday night.
There is now little competition for EpiPen, with the only rival product being Adrenaclick, which carries a list price of $461.
Mylan NV CEO Heather Bresch defended the price hikes last week, saying the company only received $274 of the total price for a twin-package while insurers, pharmacies and other parties divvy up the rest. Sanofi SA has pulled its device from the market a year ago on concerns of inaccurate doseage. Relief could come sooner from Imprimis Pharmaceuticals, a compounding pharmacy that prepares medicines to fill individual prescriptions.
Advertisement
In pre-market activity on Nasdaq, shares were gaining 2.16 percent to trade at $43.96.
